Drawing for CONTRA-MAB

USPTO serial 99706801

CONTRA-MAB

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
CRUZADO, SAMANTHA LEE
Law office
TMO LAW OFFICE 116

What this means

Status 680 means the examining attorney approved your mark for publication in the USPTO Official Gazette. Publication for opposition usually follows within weeks, opening a 30-day window for third parties to oppose. Watch for publication (status 686) and monitor the 30-day opposition window.

Status 680: Status 680 means the examining attorney approved your mark for publication in the USPTO Official Gazette. Publication for opposition usually follows within weeks, opening a 30-day window for third parties to oppose.

Need help with CONTRA-MAB?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Andrew D. Skale

Andrew D. Skale Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.3580 Carmel Mountain RoadSuite 300San Diego, CA 92130

Goods and services

ClassDescriptionStatusFirst use
042Discovery and development of engineered modular protein formats being drug discovery services; Discovery and development of new drug candidate material, namely, drug discovery services; Research and development of therapeutic antibodies and pharmaceuticals, and research and development of technology in the field of therapeutic antibodies and pharmaceuticals; Drug Discovery services, and research, and development services in the field of pharmaceutical preparations and substances; Drug Discovery services, and research, and development of therapeutic antibodies and pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical, therapeutic, and diagnostic drug discovery services; Medical research in the field nature of engineered modular protein formatsACTIVEApr 6, 2026

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 30, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 8, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 8, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 8, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 23, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 23, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 23, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 23, 2026IUAAUSE AMENDMENT ACCEPTED—
Jul 20, 2026DOCKASSIGNED TO EXAMINER—
Jul 17, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 13, 2026AUPCAMENDMENT TO USE PROCESSING COMPLETE—
Apr 13, 2026IUAFUSE AMENDMENT FILED—
Apr 13, 2026EAAUTEAS AMENDMENT OF USE RECEIVED—
Mar 17, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 17, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance